Platelet-derived growth factor receptor, Vascular endothelial growth factor receptor, and Janus kinase family kinases (PDGFR/VEGFR/JAK)

The PDGFR, VEGFR, and JAK family kinases represent a critical cluster of signaling proteins that regulate vascular development, cellular growth, and immune homeostasis. Platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs) are receptor tyrosine kinases (RTKs) that drive mesenchymal cell proliferation and angiogenesis, respectively, making them primary targets for anti-tumor therapies aimed at disrupting tumor blood supply and growth. Janus kinases (JAKs) are intracellular non-receptor tyrosine kinases essential for cytokine-mediated signal transduction through the JAK-STAT pathway, influencing both hematopoiesis and inflammatory responses. Dysregulation of these pathways is a hallmark of various malignancies, including solid tumors and myeloproliferative neoplasms, as well as chronic inflammatory conditions. Multi-kinase inhibitors (MKIs) are often designed to target these families simultaneously to achieve synergistic therapeutic effects, although such broad inhibition can lead to significant clinical toxicities such as hypertension and cytopenia. Understanding the interplay between these kinase families is vital for developing precision medicine strategies in oncology and immunology.

Other names

PDGFR/VEGFR/JAK inhibitorsMulti-kinase targetsAngiokinase and JAK familyTriple angiokinase and JAK cluster

Inhibition of the ATP-binding site within the kinase domain of receptor tyrosine kinases (PDGFR, VEGFR) and non-receptor tyrosine kinases (JAK), thereby preventing autophosphorylation and blocking downstream signaling cascades such as the PI3K/AKT, MAPK/ERK, and JAK/STAT pathways.